INTERVIEW: OncoMed CEO Hastings on milestones ahead

OncoMed Pharmaceuticals has no imminent plans to finance its soon-to-be seven-asset clinical pipeline by selling stock, because the cancer therapy developer's partnerships are structured in a way that "keeps us from having to raise money, which is a corporate goal for the company," chairman and CEO Paul Hastings told Scrip.